Mavorixafor hydrochloride  (Synonyms: AMD-070 hydrochloride)

Mavorixafor (AMD-070) hydrochloride is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding. Mavorixafor hydrochloride also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 nM and 9 nM, respectively^[1].

Mavorixafor (AMD-070) hydrochloride shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2)^[1]. Mavorixafor (6.6 µM; 14-21 days) hydrochloride significantly suppresses the anchorage-dependent growth of the B88-SDF-1 cells. Mavorixafor hydrochloride significantly impaires the enhanced motility of B88-SDF-1 cells. Mavorixafor hydrochloride also significantly inhibits the migration and Matrigel invasion of B88-SDF-1 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mavorixafor (2 mg/kg; po; once a day; for 49 days) hydrochloride significantly inhibits the lung metastasis of B88‑SDF‑1 cells in nude mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

385.93

C₂₁H₂₈ClN₅

880549-30-4

NCCCCN(CC1=NC2=CC=CC=C2N1)[C@H]3CCCC4=C3N=CC=C4.[H]Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88.  [Content Brief]

  [2]. Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308.  [Content Brief]